title: Recombinant porcine factor VIII: a new installment of a long story.
authors: Scientific Direction, IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
authors: P M
authors: PM
authors: Mannucci
mesh_terms: D000818:Animals; D006801:Humans; D019468:Disease Management; D005169:Factor VIII / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013552:Swine; D016896:Treatment Outcome
chemical_list: D005169:Factor VIII; D011994:Recombinant Proteins
references: Bidwell E. The purification of bovine antihaemophilic globulin. Br J Haematol 1955; 1: 35-45.
references: Macfarlane RG, Biggs R, Bidwell E. Bovine antihaemophilic globulin in the treatment of haemophilia. Lancet 1954; i: 1316-9.
references: Biggs R. Thirty years of haemophilia treatment in Oxford. Br J Haematol 1967; 13: 452-63.
references: Kernoff PB, Thomas ND, Lilley PA, Matthews KB, Goldman E, Tuddenham EG. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984; 63: 31-41.
references: Gatti L, Mannucci PM. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemost 1984; 51: 379-84.
references: Altieri DC, Capitanio AM, Mannucci PM. von Willebrand factor contaminating porcine factor VIII concentrate (Hyate C) causes platelet aggregation. Br J Haematol 1986; 63: 703-11.
references: Lozier JN, Santagostino E, Kasper CK, Teitel JM, Hay CR. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors. Semin Hematol 1993; 2(Suppl. 1): 10-21.
references: Hay CR. Porcine factor VIII: past, present and future. Haematologica 2000; 85(Suppl. 1): 21-4.
references: Hay CRM, Laurian Y, Verroust F, Preston FE, Kernoff PA. Induction of immune tolerance in patients with haemophilia A and inhibitors treated with porcine factor VIII by home therapy. Blood 1990; 76: 882-6.
references: Vyas P, Pasi J, Lee CA. Successful long-term treatment with porcine factor VIII of a patient with haemophilia and an inhibitor to factor VIII. Haemophilia 1996; 2: 240-3.
references: Morrison AF, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-20.
references: Soucie JM, Erdman DD, Evatt BL et al. Investigation of porcine parvovirus among persons with hemophilia receiving Hyate:C porcine factor VIII concentrate. Transfusion 2000; 40: 708-11.
references: Takefman DM, Wong S, Maudru T, Peden K, Wilson CA. Detection and characterization of porcine endogenous retrovirus in porcine plasma and porcine factor VIII. J Virol 2001; 75: 4551-7.
references: Giangrande PL, Kessler CM, Jenkins CE, Weatherill PJ, Webb PD. Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIII. Haemophilia 2002; 8: 798-801.
references: Toschi V. OBI-1, porcine recombinant factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human factor VIII. Curr Opin Mol Ther 2010; 12: 617-25.
references: Kruse-Jarres R, St-Louis J, Greist A et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2014; 20(Suppl. 3): 1-186.